The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationPoly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
d'AMOURS, D., DESNOYERS, S., d'SILVA, I., & POIRIER, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,815
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Survival of Resting Mature B Lymphocytes Depends on BCR Signaling via the Igα/β Heterodimer
Kraus, M., Alimzhanov, M. B., Rajewsky, N., & Rajewsky, K. (2004) · Cell · doi:10.1016/j.cell.2004.05.014 · Cited by 572
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Cancer risks among BRCA1 and BRCA2 mutation carriers
Levy-Lahad, E., & Friedman, E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603535 · Cited by 327
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
Schultz, N. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg703 · Cited by 301
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Coleman, R. L., Sill, M. W., Bell-McGuinn, K., Aghajanian, C., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T. J., Chan, J. K., Chen, A., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 265
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability
Fagagna, F. D. D., Hande, M. P., Tong, W.-M., Lansdorp, P. M., Wang, Z.-Q., & Jackson, S. P. (1999) · Nature Genetics · doi:10.1038/12680 · Cited by 255
Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
Evers, B., & Jonkers, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209871 · Cited by 251
Kummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
Liu, J. F., Tolaney, S. M., Birrer, M., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.020 · Cited by 174
Liu, X., Shi, Y., Maag, D. X., Palma, J. P., Patterson, M. J., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167
Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma
Patel, P. H., Chadalavada, R. S. V., Chaganti, R. S. K., & Motzer, R. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2254 · Cited by 165
Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis
Tong, W.-M., Cortes, U., & Wang, Z.-Q. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00035-x · Cited by 163
Histone H2AX is integral to hypoxia-driven neovascularization
Economopoulou, M., Langer, H. F., Celeste, A., Orlova, V. V., Choi, E. Y., Ma, M., Vassilopoulos, A., Callén, E., Deng, C., Bassing, C. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.1947 · Cited by 146
Dann, R. B., DeLoia, J. A., Timms, K. M., Zorn, K. K., Potter, J., Flake, D. D., Lanchbury, J. S. S., & Krivak, T. C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.006 · Cited by 141
Fraser, M. E., Zhao, H. W., Luoto, K. R., Lundin, C., Coackley, C. L., Chan, N. H. L., Joshua, A. M., Bismar, T. A., Evans, A. J., Helleday, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2189 · Cited by 138
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Forster, M. D., Dedes, K. J., Sandhu, S. K., Frentzas, S., Kristeleit, R. S., Ashworth, A., Poole, C. J., Weigelt, B., Kaye, S. B., & Molife, L. R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.42 · Cited by 128
Dean, E. J., Middleton, M. R., Pwint, T. P., Swaisland, H., Carmichael, J., Goodege, P., & Ranson, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.555 · Cited by 125
Gallagher, D. J., Konner, J. A., Bell-McGuinn, K. M., Bhatia, J., Sabbatini, P. J., Aghajanian, C. A., Offit, K., Barakat, R. R., Spriggs, D. R., & Kauff, N. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq577 · Cited by 118
Hay, T., Matthews, J. R., Pietzka, L., Lau, A., Cranston, A. N., Nygren, A. O. H., Douglas-Jones, A. G., Smith, G. C. M., Martin, N. M. B., O’Connor, M. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2388 · Cited by 114
Safra, T., Borgato, L., Nicoletto, M. O., Rolnitzky, L. M., Pelles-Avraham, S., Geva, R., Donach, M. E., Curtin, J. P., Novetsky, A. P., Grenader, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0272 · Cited by 94
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 91
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?
Schuyer, M., & Berns, E. M. J. J. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00117-3 · Cited by 81
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Bono, J. S. D., Mina, L. A., Gonzalez, M., Curtin, N. J., Wang, E., Henshaw, J. W., Chadha, M. K., Sachdev, J. C., Matei, D. E., Jameson, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2580 · Cited by 76
Oza, A. M., Cibula, D., Oaknin, A., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.5001 · Cited by 66
The role of targeted therapy in ovarian cancer
Banerjee, S. N., & Kaye, S. B. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70155-1 · Cited by 56
Cytogenetic Instability in Ovarian Epithelial Cells from Women at Risk of Ovarian Cancer
Pejovic, T. B., Yates, J. E., Liu, H. Y., Hays, L. E., Akkari, Y. M. N., Torimaru, Y., Keeble, W. W., Rathbun, R. K., Rodgers, W. H., Bale, A. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0222 · Cited by 55
Lee, S. A., Lopez‐Roques, C., Magwood, A. C., Masson, J., & Baker, M. D. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.10.002 · Cited by 43
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5505 · Cited by 40
Self-citationHereditary ovarian cancer: recent molecular insights and their impact on screening strategies
Long, K. C., & Kauff, N. D. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283499da9 · Cited by 28
Lee, J., Annunziata, C. M., Minasian, L. M., Zujewski, J. A., Prindiville, S. A., Kotz, H. L., Squires, J., Houston, N. D., Ji, J. J., Yu, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2520 · Cited by 24
Self-citationKristeleit, R. S., Shapiro, G. I., LoRusso, P. M., Infante, J. R., Flynn, M., Patel, M. R., Tolaney, S. M., Hilton, J. F., Calvert, H., Giordano, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2585 · Cited by 24
Gupta, A., Moreno, V., Dean, E. J., Drew, Y., Nicum, S., Ranson, M., Plummer, R., Swaisland, H., Burke, W., McCormack, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3051 · Cited by 11
Cited by
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
Self-citation
Metadata
- Authors
- Lee, J.-M., Ledermann, J. A., & Kohn, E. C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 25
- Issue
- 1
- Pages
- 32-40
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2106951948
- Cited by
- 352
- References
- 72
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.